Exploring Anticholinergic Burden in a Psychiatric Inpatient Population

Why It Matters

High anticholinergic burden is linked to cognitive impairment, falls, and increased mortality, making it a critical safety issue for vulnerable psychiatric patients. Systematic monitoring can reduce adverse events and health‑care costs.

Key Takeaways

• 75%+ patients exceed clinically significant anticholinergic threshold
• Average anticholinergic toxicity score remained around eight
• No significant seasonal variation in anticholinergic burden
• Polypharmacy drives high anticholinergic exposure in psychiatry
• Deprescribing can improve outcomes and quality of life

Pulse Analysis

Anticholinergic burden (ACB) has emerged as a silent driver of adverse drug events, especially in populations already at risk for cognitive decline. While the general elderly population has been the focus of most ACB research, psychiatric inpatients often receive complex regimens that combine psychotropics with medical drugs, amplifying the cumulative anticholinergic load. Recent epidemiologic data show a steady rise in prescriptions of high‑potency anticholinergic agents, such as certain antidepressants and antihistamines, which can precipitate delirium, constipation, and urinary retention. Understanding the pharmacodynamic additive effects of these agents is essential for clinicians aiming to balance therapeutic efficacy with safety.

The Innovations in Clinical Neuroscience study examined 250 adult inpatients across two seasonal cohorts, applying the Anticholinergic Toxicity Score (ATS) to quantify burden. An average ATS of eight—well above the five‑point clinical significance cutoff—was observed, with 75% to 78% of patients surpassing this threshold regardless of season. These findings align with prior geriatric studies that link high ACB to increased mortality, yet they highlight a gap in psychiatric settings where routine ACB assessment is rarely performed. The lack of seasonal variation suggests that prescribing patterns, rather than external factors, drive the sustained high burden.

For health systems, the implications are clear: integrating ACB screening into electronic health records can flag high‑risk regimens, prompting pharmacist‑led medication reviews. Deprescribing non‑essential anticholinergic agents or substituting them with lower‑risk alternatives can mitigate cognitive side effects and potentially reduce length of stay. Moreover, policy initiatives that incorporate ACB metrics into quality‑of‑care dashboards may incentivize prescribers to adopt safer polypharmacy practices. Future research should explore longitudinal outcomes of ACB reduction interventions in psychiatric cohorts, providing a roadmap for evidence‑based stewardship.